查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年肾臟和泌尿外科设备的全球市场
市场调查报告书
商品编码
1153821

2022-2029 年肾臟和泌尿外科设备的全球市场

Global Nephrology and Urology Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球肾臟和泌尿外科器械市场预计 2021 年将达到 50.1563 亿美元，2029 年将达到 159.4792 亿美元，预测期内（2022-2029 年）的复合年增长率据称将保持在 15.68%。

干细胞是未分化的细胞，可以通过细胞分裂无限地自我更新。此外，这些细胞可以分化成具有特定功能的更成熟的细胞。干细胞现在用于治疗 80 多种令人头疼的疾病。肾臟和泌尿外科设备正在通过收集、提取和冷冻保存干细胞和其他免疫系统细胞来探索未来潜在的医疗用途。

市场动态

人们对干细胞治疗潜力的认识不断提高，这推动了对这些诊断产品的需求不断增加。此外，新技术的进步和研发费用的增加也是推动市场增长的因素。所有这些因素都有望推动市场增长。

越来越多的新产品发布和加强研发将推动市场增长。

肾臟和泌尿外科设备的全球市场在很大程度上是由人们对干细胞治疗潜力的认识不断提高所推动的。此外，干细胞保存、加工和储存方面的新技术进步也推动了市场的增长。造血干细胞移植的增加和基于干细胞研究的投资增加进一步推动了肾臟和泌尿外科设备的发展。新兴经济体、全球主要疾病负担的增加、高出生率、GDP 增长和可支配收入的增加为主要参与者提供了市场机会。例如，2021 年 9 月，干细胞库和诊断解决方案提供商 LifeCell 宣布其新疗法 Mesocel 将获得印度 DGCI（药物管制总局）治疗 COVID-19 的临床试验批准。宣布已收购Mesocel 来源于从捐赠的脐带组织中获得的间充质干细胞。这使得能够治疗患有危及生命的 COVID-19 肺炎和急性呼吸窘迫的患者。临床试验将分两个阶段进行。

各种资金、新技术进步以及越来越多的最新创新产品发布导致对这些肾臟和泌尿外科设备的高需求。例如，2021 年 3 月，肾臟和泌尿设备公司 LifeCell 将为银行会员社区推出其首个服务 StemMatch，旨在提供有关可在 LifeCell 註册表中匹配的干细胞单元的确切质量和数量的信息。已经开始。

肾臟和泌尿外科设备的高治疗和运营成本阻碍了市场增长。

然而，肾臟和泌尿外科设备的高运营成本、干细胞采集过程中的法律和伦理问题、严格的监管框架以及低接受度和认可度可能会阻碍市场的进步。这些干细胞疗法的高成本阻碍了市场增长。据干细胞治疗创新诊所 DVC Stem 称，其 IRB 批准的间充质干细胞 (MSC) 方案预计成本约为 25,000 美元。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健行业。由于 COVID，肾臟和泌尿外科设备市场遭受了巨大损失，所有研究和临床试验都受到对 COVID 的关注的影响。但现在，市场进入者正在改变他们的长期和短期增长战略，利用研究市场和创造尖端项目来对抗这一流行病。世界各地正在发生各种倡议、合作和合併，促进了市场的增长。例如，2022 年 8 月，脐带血再生疗法製造商 StemCyte 宣布获得美国食品和药物管理局的批准，可以使用脐带血干细胞疗法对 COVID 后综合征进行 2 期临床试验。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 新产品发布次数增加
      • 增加研发
    • 约束因素
      • 与干细胞疗法相关的高费用
    • 商机
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 未满足的需求
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 透析器
  • 尿路结石治疗仪
  • 尿失禁和盆腔器官脱垂装置
  • 良性前列腺增生治疗装置
  • 内窥镜设备
  • 其他

第八章应用

  • 肾臟疾病
  • 膀胱疾病
  • 泌尿系统癌症
  • 其他

第 9 章最终用户

  • 医院
  • 专科中心
  • 门诊手术中心
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • Medtronic Plc
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Baxter International, Inc.
  • Asahi Kasei Corporation
  • B.Braun Group
  • Boston Scientific Corporation
  • Coloplast AS
  • Dornier MedTech
  • Terumo Corporation
  • Fresenius Medical Care
  • Nipro Corporation

第13章 全球肾臟和泌尿外科设备市场-DataM

简介目录
Product Code: DMOT862

Market Overview

The global Nephrology and Urology Devices market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).

Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Nephrology and Urology Devices is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.

Market Dynamics

The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.

The increasing number of novel product launches and the rising research and development will drive market growth.

The global market for Nephrology and Urology Devices is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel Nephrology and Urology Devices. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these Nephrology and Urology Devices. For instance, in Mar 2021, LifeCell, a Nephrology and Urology Devices company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.

The high therapy and operational costs associated with Nephrology and Urology Devices will hamper the market's growth.

However, the high operational costs of Nephrology and Urology Devices and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The Nephrology and Urology Devices market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.

Segment Analysis

The umbilical cord-derived stem cells segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global Nephrology and Urology Devices market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell Type. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.

Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.

Geographical Analysis

North America holds the largest market share of the global Nephrology and Urology Devices market.

North America dominates the global Nephrology and Urology Devices market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.

Competitive Landscape

The Nephrology and Urology Devices market is highly competitive with local and global companies' presence. Medtronic Plc, Baxter International, Inc., Asahi Kasei Corporation, B.Braun Group, Boston Scientific Corporation, Coloplast AS, Dornier MedTech, Terumo Corporation, Fresenius Medical Care, Nipro Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Medtronic announced the data that shows the advantages of simple blood pressure procedures of symplicity spyral renal denervation system for achieving a targeted range of levels of blood pressure.

Medtronic Plc:

Overview:

Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The Company has two operating divisions. It focuses on hematology, immunology, neuroscience, ophthalmology, cardiovascular, respiratory & allergy, and solid tumors. It was established in 1949 and is headquartered in Dublin, Ireland.

Product Portfolio:

MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.

Key Development: In May 2022, Medtronic and DaVita Inc. announced their intention to make a novel, independent medical device company that will focus on kidney care to increase the treatment experience of patients.

The global Nephrology and Urology Devices market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with stem cell therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Dialysis devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Urinary stone treatment devices
  • 7.4. Urinary incontinence & pelvic organ prolapse devices
  • 7.5. Benign prostatic hyperplasia (BPH) treatment devices
  • 7.6. Endoscopy devices
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Kidney Disease *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Bladder Disorder
  • 8.4. Urological Cancer
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Centres
  • 9.4. Ambulatory Surgical Centres
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Medtronic Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Baxter International, Inc.
  • 12.3. Asahi Kasei Corporation
  • 12.4. B.Braun Group
  • 12.5. Boston Scientific Corporation
  • 12.6. Coloplast AS
  • 12.7. Dornier MedTech
  • 12.8. Terumo Corporation
  • 12.9. Fresenius Medical Care
  • 12.10. Nipro Corporation

LIST NOT EXHAUSTIVE

13. Global Nephrology and Urology Devices Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us